Literature DB >> 8429654

Transhiatal esophagectomy for benign and malignant disease.

M B Orringer1, B Marshall, M C Stirling.   

Abstract

Transhiatal esophagectomy has been performed in 583 patients with diseases of the intrathoracic esophagus: 166 (28%) benign and 417 (72%) malignant (6% upper, 28% middle, and 66% lower third and cardia). The benign esophageal diseases included strictures (40%); neuromotor dysfunction-achalasia (24%), esophageal spasm (8%); recurrent gastroesophageal reflux (16%); acute perforation (5%); acute caustic injury (2%); and others (3%). Among the patients with benign disease, 60% had undergone at least one prior esophageal operation. Transhiatal esophagectomy was possible in 97% of patients in whom it was attempted, 19 patients (13 with benign disease and 6 with carcinoma) requiring addition of a thoracotomy for esophageal resection. Esophageal resection and reconstruction were performed in a single operation in all but 5 patients. The esophageal substitute was positioned in the posterior mediastinum in the original esophageal bed in 96%. Stomach was used to replace the esophagus in 553 patients (95%) and colon in 28 (5%) who had undergone prior gastric resections. Overall hospital mortality was 5% in patients with benign disease and 5% in those with carcinoma. There was 1 intraoperative death caused by uncontrollable hemorrhage. Complications included intraoperative entry into a pleural cavity necessitating a chest tube (74%), anastomotic leak (9%), recurrent laryngeal nerve paralysis (3%), and chylothorax and tracheal laceration (< 1% each). Three patients required reoperation for mediastinal bleeding. Average intraoperative blood loss was 875 ml (1023 ml for benign disease and 817 ml for carcinoma). Of the surviving patients, 88% were discharged able to swallow within 3 weeks of operation and 78% within 2 weeks. The actuarial survival of the patients with carcinoma is similar to that reported after more traditional transthoracic esophagectomy. Among patients with benign disease, good or excellent functional results have been achieved in nearly 70% after a cervical esophagogastric anastomosis. Although approximately 44% have required one or more anastomotic dilations within 1 to 3 months of operation, true anastomotic strictures have developed in 10%. Clinically troublesome nocturnal reflux has occurred in 3%. Transhiatal esophagectomy is feasible in most patients requiring esophageal resection for either benign or malignant disease and is a safe, well-tolerated operation if performed with care and for the proper indications.

Entities:  

Mesh:

Year:  1993        PMID: 8429654

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  47 in total

1.  Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years.

Authors:  N Ando; S Ozawa; Y Kitagawa; Y Shinozawa; M Kitajima
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

Review 2.  High grade dysplasia: surveillance, mucosal ablation, or resection?

Authors:  Robert J Korst; Nasser K Altorki
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

3.  Totally laparoscopic transhiatal esophago-gastrectomy without thoracic or cervical access. The least invasive surgery for adenocarcinoma of the cardia?

Authors:  R Costi; J Himpens; J Bruyns; G B Cadière
Journal:  Surg Endosc       Date:  2004-03-19       Impact factor: 4.584

Review 4.  Surgical resection for esophageal carcinoma: speaking the language.

Authors:  Robert J Korst
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

5.  Development of a navigation system for minimally invasive esophagectomy.

Authors:  H G Kenngott; J Neuhaus; B P Müller-Stich; I Wolf; M Vetter; H-P Meinzer; J Köninger; M W Büchler; C N Gutt
Journal:  Surg Endosc       Date:  2007-12-20       Impact factor: 4.584

6.  Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Kevin C Halling; Navtej S Buttar; Louis-Michel Wongkeesong; Alan R Zinsmeister; Shannon M Brankley; Emily G Barr Fritcher; Wytske M Westra; Kausilia K Krishnadath; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

Review 7.  Esophagectomy with gastric conduit reconstruction for benign disease: extreme but important.

Authors:  Wei Guo; Su Yang; Hecheng Li
Journal:  Ann Transl Med       Date:  2018-04

8.  Transthoracic versus transhiatal esophagectomy for esophageal carcinoma: experience from a single tertiary care institution.

Authors:  Nadeem UlNazeer Kawoosa; Abdul Majeed Dar; Mukand Lal Sharma; Abdul Gani Ahangar; Ghulam Nabi Lone; Mohammad Akbar Bhat; Shyam Singh
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

9.  Esophagectomy--it's not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer.

Authors:  Donald E Low; Sonia Kunz; Drew Schembre; Henry Otero; Tom Malpass; Alex Hsi; Guobin Song; Richard Hinke; Richard A Kozarek
Journal:  J Gastrointest Surg       Date:  2007-08-31       Impact factor: 3.452

10.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.